title: Research progress of therapeutic vaccines for treating chronic hepatitis B.
abstract: Hepatitis B virus (HBV) is a member of Hepadnavirus family, which leads to chronic infection in around 5% of patients with a high risk of developing liver cirrhosis, liver failure, and hepatocellular carcinoma.1Despite the availability of prophylactic vaccines against hepatitis B for over 3 decades, there are still more than 2 billion people have been infected and 240 million of them were chronic. Antiviral therapies currently used in the treatment of CHB (chronic hepatitis B) infection include peg-interferon, standard α-interferon and nucleos/tide analogs (NAs), but none of them can provide sustained control of viral replication. As an alternative strategy, therapeutic vaccines for CHB patients have been widely studied and showed some promising efficacies in dozens of preclinical and clinical trials. In this article, we review current research progress in several types of therapeutic vaccines for CHB treatment, including protein-based vaccines, DNA-based vaccines, live vector-based vaccines, peptide-based vaccines and cell-based therapies. These researches may provide some clues for developing new treatments in CHB infection.
authors.affiliation: a Jiangsu Theravac Bio-pharmaceutical Co., Ltd. , Nanjing , China.
authors.forename: Jianqiang
authors.initials: J
authors.lastname: Li
authors.affiliation: a Jiangsu Theravac Bio-pharmaceutical Co., Ltd. , Nanjing , China.
authors.forename: Mengru
authors.initials: M
authors.lastname: Bao
authors.affiliation: a Jiangsu Theravac Bio-pharmaceutical Co., Ltd. , Nanjing , China.
authors.forename: Jun
authors.initials: J
authors.lastname: Ge
authors.affiliation: a Jiangsu Theravac Bio-pharmaceutical Co., Ltd. , Nanjing , China.
authors.forename: Sulin
authors.initials: S
authors.lastname: Ren
authors.affiliation: a Jiangsu Theravac Bio-pharmaceutical Co., Ltd. , Nanjing , China.
authors.forename: Tong
authors.initials: T
authors.lastname: Zhou
authors.affiliation: a Jiangsu Theravac Bio-pharmaceutical Co., Ltd. , Nanjing , China.
authors.forename: Fengchun
authors.initials: F
authors.lastname: Qi
authors.affiliation: b School of Life Science and Engineering, Lanzhou University of Technology , Lanzhou , China.
authors.forename: Xiuying
authors.initials: X
authors.lastname: Pu
authors.affiliation: c Dalian Institute for Drug Control , Dalian , China.
authors.forename: Jia
authors.initials: J
authors.lastname: Dou
mesh_terms: D002986:Clinical Trials as Topic; D055808:Drug Discovery; D006509:Hepatitis B / Q000628:therapy; D006514:Hepatitis B Surface Antigens / Q000737:chemistry / Q000276:immunology; D017325:Hepatitis B Vaccines / Q000737:chemistry / Q000145:classification / Q000627:therapeutic use*; D019694:Hepatitis B, Chronic / Q000188:drug therapy / Q000628:therapy*; D006801:Humans; D019444:Vaccines, DNA / Q000008:administration & dosage / Q000627:therapeutic use; D022223:Vaccines, Subunit / Q000008:administration & dosage / Q000627:therapeutic use; D014779:Virus Replication / Q000187:drug effects
chemical_list: D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines; D019444:Vaccines, DNA; D022223:Vaccines, Subunit
keywords: Hepatitis B virus; chronic hepatitis B; therapeutic vaccine